您的位置: 首页 > 2016年5月 第47卷 第3期 > 文字全文
2023年7月 第38卷 第7期11
目录

氟伐他汀联合环磷腺苷葡胺治疗慢性肺心病急性加重期疗效观察

Observation of the clinical efficacy of Fluvastatin combined with Meglumine Adenosine Cyclophosphate on acute exacerbation of chronic pulmonary heart disease

来源期刊: 广州医药 | 66-68 发布时间:2021-11-30 收稿时间:2025/11/13 17:01:19 阅读量:22
作者:
关键词:
肺心病氟伐他汀环磷腺苷葡胺
Pulmonary heart diseaseFluvastatinMeglumine Adenosine Cyclophosphate
DOI:
10.3969/j.issn.1000-8535.2016.03.024
收稿时间:
2016-01-26 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 观察氟伐他汀联合环磷腺苷葡胺治疗慢性肺心病急性加重期的临床疗效。方法 将我院收治的74例慢性肺心病急性加重期病人,使用随机数字表法分为联合用药组与对照组,每组各37例。对照组单独使用环磷腺苷葡胺,联合用药组在对照组的基础上加服氟伐他汀。两组疗程均为7周。观察比较两组患者治疗前后的NO,ET-1,CRP,PaO2水平以及治疗效果。结果 经7周疗程治疗后,对照组有效率为64.86%,联合用药组94.59%。两组间比较,差异有统计学意义(P<0.05)。两组NO,ET-1,CRP,PaO2水平比较,联合用药组均优于对照组,差异有统计学意义(P<0.05)。结论 氟伐他汀联合环磷腺苷葡胺治疗慢性肺心病急性加重期的临床疗效更为显著,值得临床推广。
Objective To observe the clinical efficacy of combined treatment of Fluvastatin combined with Meglumine Adenosine Cyclophosphate on acute exacerbation of chronic pulmonary heart disease. Methods 74 patients with acute exacerbation of chronic pulmonary heart disease were randomly divided into combined treatment group and control group. The control group was treated by Meglumine Adenosine Cyclophosphate for 7 weeks.The combined treatment group was treated by Meglumine Adenosine Cyclophosphate and Fluvastatin for 7 weeks. The clinical efficacy and the score of NO,CRP,ET-1,PaO2 were assessed before and after the treatment. Results After 7 weeks treatment, the total clinical efficacy rate was 64.86% in the control group and 94.59% in the combined treatment group. The differences between them has statistically significant(P<0.05). The score of NO,ET-1,CRP,PaO2 in combined treatment group were significantly improved compared to control group (P<0.05). Conclusion The clinical efficacy of Fluvastatin combined with Meglumine Adenosine Cyclophosphate on acute exacerbation of chronic pulmonary heart disease is more efficient. It is worth to develop clinically.
1、 MENEVEAU N,MING LP,SERONDE MF,et al. In hospital and long term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy[J]. Eur Heart J,2013,24(2):1447-1454. MENEVEAU N,MING LP,SERONDE MF,et al. In hospital and long term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy[J]. Eur Heart J,2013,24(2):1447-1454.
2、 张义林, 宣疆英. 环磷腺苷葡胺对老年心力衰竭患者心功能及BNP水平的影响[J]. 心脑血管病防治, 2014,14(1): 74-76. 张义林, 宣疆英. 环磷腺苷葡胺对老年心力衰竭患者心功能及BNP水平的影响[J]. 心脑血管病防治, 2014,14(1): 74-76.
3、 蒋永春, 徐斌. 氟伐他汀对慢性心力衰竭患者心功能的影响 [J]. 今日药学, 2009(12): 47-48. 蒋永春, 徐斌. 氟伐他汀对慢性心力衰竭患者心功能的影响 [J]. 今日药学, 2009(12): 47-48.
4、 党静.辛伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压疗效观察[J]. 中国医药指南,2011.9(20):23-24. 党静.辛伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压疗效观察[J]. 中国医药指南,2011.9(20):23-24.
5、 TAM A,SIN DD.Pathobiologic mechanisms of chronic obstmctive pulmonary disease[J]. Med cIin North Am,2012,96(4):68l-698. TAM A,SIN DD.Pathobiologic mechanisms of chronic obstmctive pulmonary disease[J]. Med cIin North Am,2012,96(4):68l-698.
6、 袁东运.依那普利与丹参酮治疗肺心病急性加重期患者的疗效观察及对血液流变学的影响[J]. 中国中医药科技,2010,17(3): 241. 袁东运.依那普利与丹参酮治疗肺心病急性加重期患者的疗效观察及对血液流变学的影响[J]. 中国中医药科技,2010,17(3): 241.
7、 全国慢性肺心病协作组 . 慢性肺心病的防治研究[M]. 北京: 人民卫生出版社, 2001:193. 全国慢性肺心病协作组 . 慢性肺心病的防治研究[M]. 北京: 人民卫生出版社, 2001:193.
8、 苏州. 环磷腺苷联合阿魏酸钠治疗慢性肾衰竭周围神经病变的疗效观察[J]. 现代药物与临床, 2015,30(4): 433-435. 苏州. 环磷腺苷联合阿魏酸钠治疗慢性肾衰竭周围神经病变的疗效观察[J]. 现代药物与临床, 2015,30(4): 433-435.
9、 谭章华,赵娇. 氟伐他汀和非诺贝特治疗糖尿病合并高血脂症疗效观察[J]. 现代中西医结合杂志,2014,23(4): 395-397. 谭章华,赵娇. 氟伐他汀和非诺贝特治疗糖尿病合并高血脂症疗效观察[J]. 现代中西医结合杂志,2014,23(4): 395-397.
10、 李顶.阿魏酸钠治疗肺心病急性加重期100例临床分析[J]. 中西医结合心脑血管病杂志,2011,9(5):618-619. 李顶.阿魏酸钠治疗肺心病急性加重期100例临床分析[J]. 中西医结合心脑血管病杂志,2011,9(5):618-619.
11、 薛蕾,刘伦军.加用丹红注射液治疗高原地区慢性肺心病急性发作的疗效观察[J]. 现代临床医学,2010,36(6):461-462. 薛蕾,刘伦军.加用丹红注射液治疗高原地区慢性肺心病急性发作的疗效观察[J]. 现代临床医学,2010,36(6):461-462.
12、 黄斌,张晓云,王筠.中西医结合治疗肺源性心脏病急性发作期合并呼吸衰竭临床研究[J]. 中国中医急症,2010,3(19):372-373,411. 黄斌,张晓云,王筠.中西医结合治疗肺源性心脏病急性发作期合并呼吸衰竭临床研究[J]. 中国中医急症,2010,3(19):372-373,411.
13、 LEWCZUK J. Chronic pulmonary hean disease. Does it require cardiologist 7s attention[J]. Kardiol Pol,2013,7l(1):84-87. LEWCZUK J. Chronic pulmonary hean disease. Does it require cardiologist 7s attention[J]. Kardiol Pol,2013,7l(1):84-87.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录